Sign inJoin free

Watch / Small Cap

BCAL Diagnostics chases US upside with validation partner

2 June 20268:28

BCAL Diagnostics chases US upside with validation partner

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key Points:

  • Long-term collaboration with Sonic Healthcare to validate and launch BCAL’s breast test in the US

  • Expansion from single breast test to a broader oncology blood test portfolio, including ovarian, pancreatic and planned multi-cancer test

  • Digital integration with major Australian GP and specialist software platforms to streamline referrals

  • Strong focus on reimbursement and lowering test costs over time to improve accessibility

BCAL Diagnostics (ASX:BDX) is, in executive chair Jayne Shaw’s view, entering a key commercial phase as it advances its breast and multi-cancer blood test portfolio. Jayne Shaw states that BCAL has been developing a blood test to rule out breast cancer for 15 years, launching the first version in Sydney last year, with a second-generation test targeted for September. Shaw highlights a long-standing collaboration with Sonic Healthcare, now extending to the US where Sonic, described as the third-largest pathology provider, is set to undertake external validation and support market entry and reimbursement pathways.

Shaw outlines a broader oncology diagnostics platform, including blood tests for ovarian and pancreatic cancer via a partnership with ClearNote Health, and a planned multi‑cancer blood test covering eight cancers later this year. In Australia, BCAL’s tests are accessible through the EarlyDetection.com portal, integrated with MedicalDirector, Best Practice and Genie Solutions, which Shaw views as crucial digital infrastructure to scale referrals from GPs and specialists.

On funding, Shaw describes BCAL as having a solid balance sheet, with cash visibility into March–April next year, but stresses that reimbursement is critical. Current pricing is cited at about $1,400 for pancreatic and ovarian tests and $300 for the breast test, with a long‑term aim to materially reduce costs through technology transfer and scale.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy